piR-61298 promotes colorectal cancer progression through destabilizing p53 by interacting with USP10

Abstract

PIWI-interacting RNAs (piRNAs) are a class of noncoding RNAs primarily found in germ cells. While piRNAs are known to be involved in various cancers, their specific roles in colorectal cancer (CRC) remain unclear. To elucidate the role of piRNAs in CRC, we first analyzed their expression characteristics by sequencing 10 pairs of tumor and adjacent normal tissues. Subsequently, differentially expressed piRNAs were identified through a two-stage reverse transcription-quantitative PCR (RT-qPCR) validation using 20 and 114 pairs of samples. Subcellular localization was assessed through nucleoplasmic separation and immunofluorescence staining assays. RNA pull-down mass spectrometry was employed to identify piRNA-interacting proteins. We identified piR-61298 as a piRNA significantly upregulated in CRC. Functional assays showed that piR-61298 promoted cell proliferation and migration, inhibited apoptosis, and promoted tumor growth. Mechanistically, piR-61298 bound to ubiquitin-specific peptidase 10 (USP10) in the cytoplasm, impairing its deubiquitinating activity toward p53, thereby leading to p53 ubiquitination and degradation. These findings suggest that piR-61298 plays a critical role in CRC progression by disrupting the USP10-p53 axis. Collectively, the current study highlights piR-61298 as a potential therapeutic target, offering a novel approach for CRC treatment by targeting piRNA-mediated regulation.

Keywords

piRNA / colorectal cancer / USP10 / p53 / deubiquitination

Funding

This work received no funding from any source.

Acknowledgments

We sincerely appreciate the invaluable guidance and constructive suggestions provided by Professor Meilin Wang from the School of Public Health, Nanjing Medical University, in support of this study.

Author contributions

Shenya Xu: Conceptualization, Methodology, Investigation, Formal analysis, Visualization, Writing—original draft. Zhutao Ding: Methodology, Data curation, Validation, Formal analysis, Writing —original draft. Shuai Ben: Investigation, Validation, Data curation, Visualization. Chen Li: Methodology, Formal analysis. Silu Chen: Investigation, Validation. Lingyan Zhao: Data curation. Shuwei Li: Conceptualization, Supervision, Writing —review & editing, Funding acquisition. Dongying Gu: Supervision, Project administration, Resources, Writing —review & editing, Funding acquisition.

Additional information

The online version contains supplementary material available at http://www.jbr-pub.org.cn/article/doi/10.7555/JBR.39.20250137?pageType=en.

References

[1] Miller KD, Nogueira L, Devasia T, et al. Cancer treatment and survivorship statistics, 2022[J]. CA Cancer J Clin, 2022, 72(5): 409-436. doi: 10.3322/caac.21731

[2] Zheng X, Wang Q, Zhou Y, et al. N-acetyltransferase 10 promotes colon cancer progression by inhibiting ferroptosis through N4-acetylation and stabilization of ferroptosis suppressor protein 1 (FSP1) mRNA[J]. Cancer Commun (Lond), 2022, 42(12): 1347-1366. doi: 10.1002/cac2.12363

[3] Xue C, Chu Q, Zheng Q, et al. Role of main RNA modifications in cancer: N⁶-methyladenosine, 5-methylcytosine, and pseudouridine[J]. Signal Transduct Target Ther, 2022, 7(1): 142. doi: 10.1038/s41392-022-01003-0

[4] Gao R, Wu C, Zhu Y, et al. Integrated analysis of colorectal cancer reveals cross-cohort gut microbial signatures and associated serum metabolites[J]. Gastroenterology, 2022, 163(4): 1024-1037.E9. doi: 10.1053/j.gastro.2022.06.069

[5] Song M, Chan AT, Sun J. Influence of the gut microbiome, diet, and environment on risk of colorectal cancer[J]. Gastroenterology, 2020, 158(2): 322-340. doi: 10.1053/j.gastro.2019.06.048

[6] Liu Y, Dou M, Song X, et al. The emerging role of the piRNA/piwi complex in cancer[J]. Mol Cancer, 2019, 18(1): 123. doi: 10.1186/s12943-019-1052-9

[7] Wang X, Ramat A, Simonelig M, et al. Emerging roles and functional mechanisms of PIWI-interacting RNAs[J]. Nat Rev Mol Cell Biol, 2023, 24(2): 123-141. doi: 10.1038/s41580-022-00528-0

[8] Jiang M, Hong X, Gao Y, et al. piRNA associates with immune diseases[J]. Cell Commun Signal, 2024, 22(1): 347. doi: 10.1186/s12964-024-01724-5

[9] Li F, Yuan P, Rao M, et al. piRNA-independent function of PIWIL1 as a co-activator for anaphase promoting complex/cyclosome to drive pancreatic cancer metastasis[J]. Nat Cell Biol, 2020, 22(4): 425-438. doi: 10.1038/s41556-020-0486-z

[10] Han H, Fan G, Song S, et al. piRNA-30473 contributes to tumorigenesis and poor prognosis by regulating m⁶A RNA methylation in DLBCL[J]. Blood, 2021, 137(12): 1603-1614. doi: 10.1182/blood.2019003764

[11] Sun T, Liu Z, Yang Q. The role of ubiquitination and deubiquitination in cancer metabolism[J]. Mol Cancer, 2020, 19(1): 146. doi: 10.1186/s12943-020-01262-x

[12] Cai C, Tang Y, Zhai J, et al. The RING finger protein family in health and disease[J]. Signal Transduct Target Ther, 2022, 7(1): 300. doi: 10.1038/s41392-022-01152-2

[13] Bernassola F, Chillemi G, Melino G. HECT-type E3 ubiquitin ligases in cancer[J]. Trends Biochem Sci, 2019, 44(12): 1057-1075. doi: 10.1016/j.tibs.2019.08.004

[14] Li Q, Fang X, Li Y, et al. DCAF7 acts as a scaffold to recruit USP10 for G3BP1 deubiquitylation and facilitates chemoresistance and metastasis in nasopharyngeal carcinoma[J]. Adv Sci (Weinh), 2024, 11(36): e2403262. doi: 10.1002/advs.202403262

[15] Zhu H, Yan F, Yuan T, et al. USP10 promotes proliferation of hepatocellular carcinoma by deubiquitinating and stabilizing YAP/TAZ[J]. Cancer Res, 2020, 80(11): 2204-2216. doi: 10.1158/0008-5472.CAN-19-2388

[16] Tassinari M, Richter SN, Gandellini P. Biological relevance and therapeutic potential of G-quadruplex structures in the human noncoding transcriptome[J]. Nucleic Acids Res, 2021, 49(7): 3617-3633. doi: 10.1093/nar/gkab127

[17] Mai D, Ding P, Tan L, et al. PIWI-interacting RNA-54265 is oncogenic and a potential therapeutic target in colorectal adenocarcinoma[J]. Theranostics, 2018, 8(19): 5213-5230. doi: 10.7150/thno.28001

[18] Feng J, Yang M, Wei Q, et al. Novel evidence for oncogenic piRNA-823 as a promising prognostic biomarker and a potential therapeutic target in colorectal cancer[J]. J Cell Mol Med, 2020, 24(16): 9028-9040. doi: 10.1111/jcmm.15537

[19] Weng W, Liu N, Toiyama Y, et al. Novel evidence for a PIWI-interacting RNA (piRNA) as an oncogenic mediator of disease progression, and a potential prognostic biomarker in colorectal cancer[J]. Mol Cancer, 2018, 17(1): 16. doi: 10.1186/s12943-018-0767-3

[20] Liu F, Chen J, Li K, et al. Ubiquitination and deubiquitination in cancer: From mechanisms to novel therapeutic approaches[J]. Mol Cancer, 2024, 23(1): 148. doi: 10.1186/s12943-024-02046-3

[21] Li B, Qi Z, He D, et al. NLRP7 deubiquitination by USP10 promotes tumor progression and tumor-associated macrophage polarization in colorectal cancer[J]. J Exp Clin Cancer Res, 2021, 40(1): 126. doi: 10.1186/s13046-021-01920-y

[22] Ma Z, Feng Y, Guo K, et al. Melatonin inhibits ESCC tumor growth by mitigating the HDAC7/β-catenin/c-Myc positive feedback loop and suppressing the USP10-maintained HDAC7 protein stability[J]. Mil Med Res, 2022, 9(1): 54. doi: 10.1186/s40779-022-00412-0

[23] Shi J, Wu X, Wang Z, et al. A genome-wide CRISPR screen identifies WDFY3 as a regulator of macrophage efferocytosis[J]. Nat Commun, 2022, 13(1): 7929. doi: 10.1038/s41467-022-35604-8

[24] Zhang N, Wang B, Ma C, et al. LINC00240 in the 6p22.1 risk locus promotes gastric cancer progression through USP10-mediated DDX21 stabilization[J]. J Exp Clin Cancer Res, 2023, 42(1): 89. doi: 10.1186/s13046-023-02654-9

[25] Wang X, Xia S, Li H, et al. The deubiquitinase USP10 regulates KLF4 stability and suppresses lung tumorigenesis[J]. Cell Death Differ, 2020, 27(6): 1747-1764. doi: 10.1038/s41418-019-0458-7

[26] Song B, Yang P, Zhang S. Cell fate regulation governed by p53: friends or reversible foes in cancer therapy[J]. Cancer Commun (Lond), 2024, 44(3): 297-360. doi: 10.1002/cac2.12520

[27] Schubert SA, Ruano D, Joruiz SM, et al. Germline variant affecting p53β isoforms predisposes to familial cancer[J]. Nat Commun, 2024, 15(1): 8208. doi: 10.1038/s41467-024-52551-8

[28] Wang J, Yang Y, Shao F, et al. Acetate reprogrammes tumour metabolism and promotes PD-L1 expression and immune evasion by upregulating c-Myc[J]. Nat Metab, 2024, 6(5): 914-932. doi: 10.1038/s42255-024-01037-4

[29] Yang R, Chen H, Xing L, et al. Hypoxia-induced circWSB1 promotes breast cancer progression through destabilizing p53 by interacting with USP10[J]. Mol Cancer, 2022, 21(1): 88. doi: 10.1186/s12943-022-01567-z

[30] Takayama KI, Suzuki T, Fujimura T, et al. Association of USP 10 with G3BP2 inhibits p53 signaling and contributes to poor outcome in prostate cancer[J]. Mol Cancer Res, 2018, 16(5): 846-856. doi: 10.1158/1541-7786.MCR-17-0471

[31] Liu W, Deng L, Wang M, et al. Pcf11/Spt5 condensates stall RNA polymerase Ⅱ to facilitate termination and piRNA-guided heterochromatin formation[J]. Mol Cell, 2025, 85(5): 929-947. doi: 10.1016/j.molcel.2025.01.023

[32] Ben S, Ding Z, Xin J, et al. piRNA PROPER suppresses DUSP1 translation by targeting N⁶-methyladenosine-mediated RNA circularization to promote oncogenesis of prostate cancer[J]. Adv Sci (Weinh), 2024, 11(33): e2402954. doi: 10.1002/advs.202402954

[33] Mei Y, Wang Y, Kumari P, et al. A piRNA-like small RNA interacts with and modulates p-ERM proteins in human somatic cells[J]. Nat Commun, 2015, 6: 7316. doi: 10.1038/ncomms8316

[34] Ko A, Han SY, Choi CH, et al. Oncogene-induced senescence mediated by c-Myc requires USP10 dependent deubiquitination and stabilization of p14ARF[J]. Cell Death Differ, 2018, 25(6): 1050-1062. doi: 10.1038/s41418-018-0072-0

[35] Suresh B, Lee J, Kim H, et al. Regulation of pluripotency and differentiation by deubiquitinating enzymes[J]. Cell Death Differ, 2016, 23(8): 1257-1264. doi: 10.1038/cdd.2016.53

[36] Cannell IG, Merrick KA, Morandell S, et al. A pleiotropic RNA-binding protein controls distinct cell cycle checkpoints to drive resistance of p53-defective tumors to chemotherapy[J]. Cancer Cell, 2015, 28(5): 623-637. doi: 10.1016/j.ccell.2015.09.009

[37] Liu Y, Su Z, Tavana O, et al. Understanding the complexity of p53 in a new era of tumor suppression[J]. Cancer Cell, 2024, 42(6): 946-967. doi: 10.1016/j.ccell.2024.04.009

[38] Koralewska N, Corradi E, Milewski MC, et al. Short 2'-O-methyl/LNA oligomers as highly-selective inhibitors of miRNA production in vitro and in vivo[J]. Nucleic Acids Res, 2024, 52(10): 5804-5824. doi: 10.1093/nar/gkae284